Downgrade for Sonic

Scott Power


Sonic has downgraded FY15 EBITDA 3-4% lower the prior guidance to A$730m on the back of issues impacting its domestic pathology business, including lower patient volumes, fee changes to certain tests and increased collection costs. SHL also provided FY16 EBITDA guidance between A$850-875m. While this guidance reflects a 16-20% yoy increase, it sits more than 6% below consensus expectations at the mid-point. However, this guidance does not include potential earnings from the C$3bn tender win with Alberta Health Services inked last year due to “uncertainty around the commencement data”. Management will provide an update to this guidance in the coming months. While it is clearly disappointing to see SHL follow in PRY’s footsteps and downgrade FY15 estimates, the market has already marked down the stock by more than 7% which should limit the impact today. (SHL, Add, Price Target A$24.13)

1 stock mentioned

Scott Power
Scott Power
Senior Analyst

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Please sign in to comment on this wire.